Amphastar Pharmaceuticals Files 8-K on Financials

TL;DR

Amphastar dropped an 8-K on Feb 27th covering financials - check it for the deets.

AI Summary

Amphastar Pharmaceuticals, Inc. filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.

Why It Matters

This filing serves as a public notification of Amphastar Pharmaceuticals' financial reporting and operational updates, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — The filing is a standard regulatory report and does not inherently indicate new risks or significant negative events.

Key Players & Entities

• Amphastar Pharmaceuticals, Inc. (company) — Registrant
• February 27, 2025 (date) — Date of Report
• 11570 6th Street, Rancho Cucamonga, California 91730 (address) — Principal Executive Offices

FAQ

From the Filing

0001297184-25-000003.txt : 20250227 0001297184-25-000003.hdr.sgml : 20250227 20250227163314 ACCESSION NUMBER: 0001297184-25-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250227 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250227 DATE AS OF CHANGE: 20250227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amphastar Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001297184 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330702205 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36509 FILM NUMBER: 25679634 BUSINESS ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 909-980-9484 MAIL ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 8-K 1 amph-20250227x8k.htm 8-K 0001297184 false DE 0001297184 2025-02-27 2025-02-27 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ​ Date of Report (Date of earliest event Reported): February 27, 2025 ​ Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ​ ​ ​ ​ De laware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) ​ ​ ​ ​ 11570 6th Street ​ Rancho Cucamonga , California 91730 (Address of Principal Executive Offices) (Zip Code) ​ Registrant's telephone number, including area code: ( 909 ) 980-9484 ​ ​ ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Title of each class ​ Trading Symbol(s) ​ Name of each exchange on which registered Common Stock, par value $0.0001 per share ​ AMPH ​ The NASDAQ Stock Market LLC ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act . ☐ ​ ​ ​ ​ Item 2.02. Results of Operations and Financial Condition. ​ On February 27, 2025, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. ​ The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference